文献速递炎症性肠病消化道肿瘤与早癌

免疫调节剂累积暴露增加炎症性肠病女性宫颈上皮内瘤变风险

Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-05-23

该研究基于荷兰炎症性肠病生物样本库1981例女性,评估免疫调节剂与生物制剂累积暴露与宫颈高级别上皮内瘤变及宫颈癌(CIN2+)的关联。中位随访17.2年间99例(5%)发生CIN2+,免疫调节剂每暴露一年CIN2+风险增加(HR 1.16,95%CI 1.08-1.25),生物制剂累积暴露未见关联。吸烟与5年筛查频率也是CIN2+检出的危险因素。

要点

  • 免疫调节剂每累积暴露一年,CIN2+风险增加(HR 1.16,95%CI 1.08-1.25)。
  • 生物制剂或生物制剂联合免疫调节剂的累积暴露与CIN2+无关联。
  • 吸烟(HR 2.73)与5年筛查频率(HR 1.74)也是CIN2+检出的危险因素。

核心结论

  • 免疫调节剂累积暴露与炎症性肠病女性CIN2+风险增加相关;除积极咨询患者参与宫颈筛查外,长期免疫调节剂暴露女性强化筛查的获益有待进一步评估。

研究设计与样本

  • 研究纳入荷兰炎症性肠病生物样本库中2016年12月31日前确诊、且在全国细胞病理学数据库有宫颈记录的女性患者。
  • 研究队列共1981例女性,中位随访17.2年(IQR 14.6)。

主要发现

  • 99例(5%)在中位随访17.2年间发生CIN2+。
  • 1305例(66%)女性曾暴露于免疫抑制药物(免疫调节剂58%、生物制剂40%、两者均用33%)。
  • 免疫调节剂每暴露一年CIN2+风险增加(HR 1.16,95%CI 1.08-1.25)。
  • 生物制剂累积暴露及生物制剂联合免疫调节剂累积暴露与CIN2+均未观察到关联。
  • 多因素分析中,吸烟(HR 2.73,95%CI 1.77-4.37)与5年筛查频率(HR 1.74,95%CI 1.33-2.27)也是CIN2+检出的危险因素。

关键数值与推荐

  • 免疫调节剂包括硫嘌呤类、甲氨蝶呤、他克莫司和环孢素。
  • 生物制剂包括抗肿瘤坏死因子、维得利珠单抗和乌司奴单抗。
  • 采用扩展的时间依赖性Cox回归模型评估免疫抑制药物累积暴露。

临床怎么用

  • 作者认为应积极咨询炎症性肠病女性参与宫颈筛查项目。
  • 作者认为长期免疫调节剂暴露女性强化筛查的获益有待进一步评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with inflammatory bowel disease (IBD) are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+). AIM: To assess the association between cumulative exposure to immunomodulators (IM) and biologic agents (BIO) for IBD and CIN2+ METHODS: Adult women diagnosed with IBD before December 31st 2016 in the Dutch IBD biobank with available cervical records in the nationwide cytopathology database were identified. CIN2+ incidence rates in IM- (i.e., thiopurines, methotrexate, tacrolimus and cyclosporine) and BIO- (anti-tumour necrosis factor, vedolizumab and ustekinumab) exposed patients were compared to unexposed patients and risk factors were assessed. Cumulative exposure to immunosuppressive drugs was evaluated in extended time-dependent Cox-regression models. RESULTS: The study cohort comprised 1981 women with IBD: 99 (5%) developed CIN2+ during median follow-up of 17.2 years [IQR 14.6]. In total, 1305 (66%) women were exposed to immunosuppressive drugs (IM 58%, BIO 40%, IM and BIO 33%). CIN2+ risk increased per year of exposure to IM (HR 1.16, 95% CI 1.08-1.25). No association was observed between cumulative exposure to BIO or both BIO and IM and CIN2+. In multivariate analysis, smoking (HR 2.73, 95%CI 1.77-4.37) and 5-yearly screening frequency (HR 1.74, 95% CI 1.33-2.27) were also risk factors for CIN2+ detection. CONCLUSION: Cumulative exposure to IM is associated with increased risk of CIN2+ in women with IBD. In addition to active counselling of women with IBD to participate in cervical screening programs, further assessment of the benefit of intensified screening of women with IBD on long-term IM exposure is warranted.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kreijne JE, Goetgebuer RL, Erler NS, et al. Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 37221820. doi:10.1111/apt.17555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。